A lyric from one of my favorite contemporary hard rock songs is playing loudly in my head.
Let me explain. As a boomer “of a certain age,” I like to keep in shape with exercise and also remain young at heart.
That’s why I have put together a killer list of hard rock songs from modern bands like Halestorm, Pop Evil, Shinedown and Papa Roach. When I hit the gym or the slopes up at Tahoe, I have 54 playlists each with 14 songs to choose from.
And right now, I can hear Godsmack’s “I Stand Alone,” the hit song from the movie “The Scorpion King” on mental repeat.
I believe it’s an appropriate soundtrack for my 2019 tech forecast I told you about on Jan. 1. At the time, the media was barraging us with stories about an impending “recession.”
But I stood apart from the crowd and predicted a strong year tech.
With that in mind, I’m updating my forecast to show you why there’s still lots of money to be made and how to get in on the action…
Shortly before Apple Inc. (AAPL) reported its fiscal third quarter earnings yesterday, Michael appeared in a panel discussion on TD Ameritrade about what to expect from the iPhone maker. Michael argued that the firm would likely see a decline in iPhone sales, thanks in part to trade tensions with China and increased competition from local smart phone makers in that country and elsewhere. And while he wasn’t expecting any major surprises from the firm’s report, he delved into one the key factors he thinks the firm will use to continue an upward trajectory going forward – services. And indeed, services revenue climbed 12.6% to $11.46 billion, a new record for the firm, though it came in slightly under analysts’ expectations thanks in part to a one-time payment from lawsuits a year ago and foreign-exchange effects. Watch to see Michael’s prediction about the long-term prospects of the stock… Click here to watch.
A friend of mine, Ben, did what many of us dream about a few years back.
He was in middle management, deeply ensconced in a big accounting firm in downtown San Francisco. It paid great, but Ben hated the job: long hours, a ridiculous commute, tons of boring meetings, eating lunch at the desk every day. You know the routine.
But unlike so many of us, Ben took action. He regained his freedom.
He quit his job, cashed out some of his investments, moved to the country, and became an independent trucker.
He loves it. He loves chatting with other truckers, eating at greasy spoons, listening to talk radio all day, being his own boss… pretty much.
But he also hates it, sometimes. That’s because Ben’s “boss,” such as it is, is a computer that tells him where to go, when to get there, when to pull over to fill up or for maintenance, even when to go to bed.
Yup, like I tell you so often, every business is a tech business – even trucking.
A few years back, I showed you folks one way to cash in on tech’s takeover of trucking by recommending FleetCor Technologies Inc. (NYSE: FLT), a commercial fleet-focused electronic payments company. And if you made that move, you’re sitting on some pretty big gains – 135.8%.
FleetCor still has plenty of room to run – up to 20% in just the next 12 months.
But there’s another trucking technology investment out there that I want to tell you about. And I need to tell you about it now – today.
That’s because midnight, Dec. 18, a little-known federal mandate will go into effect across the United States.
It requires the immediate deployment of a cutting-edge technology for the trucking industry. It’s “Ben’s boss.”
I call it an Augmented Digital Copilot – or ADC for short. (I can’t tell you what Ben calls it.)
And just one tiny company has meticulously developed the technology to dominate this market. Only it can fulfill the immense and imminent demand for these devices.
This small, under-the-radar firm is on the verge of earning a big chunk of the $2 billion windfall that this federal mandate is creating.
That will send its stock soaring and make its investors a fortune.
The Doe has advanced by 1,000 points by five times this year… so far.
In fact, it took just 30 days for it to reach 24,000 on Nov. 30.
That’s great news for just about every investor.
But the news is even better for investors like you.
For technology investors, the Nasdaq Composite set 69 new highs so far this year. It has gained 23.3%, which is 49.5% better than the S&P 500 and 15.7% better than the Dow.
Meanwhile, Bitcoin is up 1,075% in 2017 – and Ethereum has soared an amazing 5,371.4%.
And in legal marijuana, my premium Nova-X Report members have made triple-digit gains on several of the penny pot stocks in their model portfolio. To find out how to join them, just click here.
In other words, ground-floor trends like technology, cryptocurrencies, and legal marijuana are the driving forces behind the market’s historic gains.
But that doesn’t mean you can just blindly buy any tech stock out there and expect to make money.
While I know you don’t believe that’s true, some of you might buy into Wall Street’s hype machine – and believe you can make a fortune on some of the troubled tech leaders they’re touting as “turnaround” investments in 2018.
Don’t believe that hype.
Especially don’t believe any hype you might hear about these 2018 Tech Dogs.
These are the four stocks you want to stay as far away as possible from next year. They’re dangerous – all four of them.
If you follow the chip sector, you might be confused.
Check out what’s happened in just the past month…
On Nov. 3 we learned that Marvell Technology Group Ltd.(Nasdaq: MRVL) is in talks to buy Cavium Inc. (Nasdaq: CAVM). The pact would create a chip firm worth some $14 billion but the deal is yet to be consummated.
But that was small potatoes compared to what came next.
On Nov. 13, Qualcomm Inc.(Nasdaq: QCOM) rejected a $105 billion buyout offer from Broadcom Ltd.(Nasdaq: AVGO) – what would have been the biggest tech buyout in history. As a leading supplier of mobile-chip technology, Qualcomm says it’s better off operating on its own rather than merge with.
And all that comes after Qualcomm offered $39 billion to buy NXP Semiconductors NV (Nasdaq: NXPI). At the time, that was the record amount for a chip sector takeover.
Moreover, Wall Street analysts seem to be constantly putting the semiconductor sector on “watch” – saying the current chip surge is about to run out… today… tomorrow… next week.
But they’re always wrong.
If you’re not sure where you should be putting your money after mixed messages like that, I understand. Like I said, it gets confusing.
However, you do want some money in semiconductors.
See, the chip industry is consolidating not out of weakness, but strength.
A recent report by industry trade group SEMI forecasts that silicon shipments will hit 11.49 billion square inches this year, 11.8 billion next year, and 12.24 billion in 2019. Total shipments of “wafers” – the format silicon is produced in – for this year will break the record set back in 2016. And shipments will continue at record levels for each of the next two years.
And that’s just one robust forecast – I’ll show you a couple more below.
Still, if you’re not up for picking and choosing among the acquirers and acquireds, there is a way to make money off the on again/off again Qualcomm-Broadcom merger, the Marvell-Cavium lockup, and just about any other chip-sector M&A that comes along.
For one, I’m a bit taller than the average guy. My hair went silver earlier than I expected. And I’m fortunate that it’s easier for me to keep trim than a lot of people I know.
On the downside, I’ve got various allergies and genetic maladies that most folks don’t.
My environment isn’t average either. Here in Silicon Valley and the San Francisco Bay Area, I spend my days in some of the most polluted cities in the United States. Of course, in other ways, this region rates much higher than most of America.
Then there are my habits. For example, I eat well, but don’t get to the gym enough.
I bet you’re the same way – but different.
No one is average.
And that’s why it often seems like maintaining a healthy diet, getting plenty of exercise, and regular checkups just aren’t enough to keep us healthy. If it were, no one would gain too much weight, go bald at 30, or get cancer.
By our very nature, each of us is so unique that this one-size-fits-all approach just isn’t enough.
That’s what opened the door for an emerging field known as precision medicine. The idea here is to set up disease prevention and treatment measures for each and every individual, accounting for your genes, environment, and lifestyle… for my genes, environment, and lifestyle.
Think of it as a partnership – a “convergence” – among traditional medicine, molecular biology, data analysis, and cloud computing.
Doctors and other medical diagnosticians collect our info, and then feed it to the cloud. There software and data scientists can crunch through all that data – and then use what they turn up to prescribe precise disease treatments and preventative measures for each individual.
Mordor Intelligence has run the numbers – and says precision medicine will be worth $59.2 billion by 2021
Thanks to legal recreational use of marijuana about to launch in California and nationwide up in Canada, sometimes it’s easy to forget where we got started here.
Legal marijuana first came to my attention because of the “War on Pain.”
Let me explain…
In a study a year or so ago, the National Institutes of Health (NIH) found that about 11% of Americans suffered from debilitating pain. Other sources say the number of this country’s pain sufferers may run as high as 50 million.
But I don’t need statistics to know that millions of Americans suffer from serious pain problems.
I do so myself – and so do many of my friends and family members.
And that has turned the market for pain medication into a huge business. According to market researcher VisionGain, the worldwide business for pain drugs is worth about $68 billion right now.
Other studies say it’s even bigger.
Equally huge is the nation’s opioid crisis.
President Donald Trump has declared the opioid crisis a “public health emergency,” and a White House commission has released its final report on the epidemic, calling for more drug courts, greater training for doctors, and penalties for insurers who do not cover addiction treatment.
The number of opioid-related deaths rose 75%, from roughly 20,000 in 2010 to 35,000 in 2015. In other words, opioid-based drugs kill more than 100 Americans every day.
This surge in the number of pain sufferers – coupled with the snapback against the prescription of opioid drugs – has opened the door to a wholly new approach to pain treatment.
I’m talking about medical marijuana and all its derivatives.